News
Atonco plays an active role in finding new collaborators who are highly experienced in their field of expertise and in establishing partnerships with various actors involved in the field of alphatherapy.
BLADDER CANCER, a first in France.
December 15, 2025 Spotlight on astatine-211, an alpha-emitting radionuclide with high cytotoxic potential, which represents a major step forward in nuclear medicine, within the highly promising field of targeted radiotherapy. A collaboration between Atonco and the...
STATUS OF CLINICAL ALPHATHERAPY – NOVEMBER 2025
Atonco Report: Overview of Clinical Developments in Alpha-Emitting Radiotherapy Atonco publishes its November 2025 report documenting the state of clinical research in alphatherapy worldwide. Compiled from the ClinicalTrials.gov database and recent scientific...
ATONCO ANNOUNCES THE APPOINTMENT OF DR. ALEXANDRA (GITEAU) PAILLARD AS CHIEF OPERATING OFFICER
Atonco, an innovative company specializing in the development of next-generation radiopharmaceuticals based on astatine-211, today announced the promotion of Alexandra Paillard to Chief Operating Officer, effective October 1, 2025. Following this appointment,...
ATO-101™: A THERAPEUTIC ADVANCE FOR THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
Atonco is proud to announce that the preclinical and clinical study results have been published in the Cancers (MDPI) journal, highlighting the promising potential of its radiopharmaceutical ATO-101™ ([211At]At-girentuximab) in the alpha-immunotherapy treatment using astatine-211 of non-muscle-invasive bladder cancer (NMIBC) refractory to standard therapies, including BCG.
ATONCO AND GIP ARRONAX SIGN CONTRACT TO DEVELOP AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY
Atonco and GIP ARRONAX (Saint Herblain, France) have joined forces to take the next step in the implementation of alpha-immunotherapy for cancer.
ATONCO AND UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION ON PHASE 1-2a CLINICAL STUDY OF ATO-101™
Atonco, a French biotechnology company, and University of Michigan today announced a collaborative agreement to conduct a Phase 1-2a clinical study evaluating Atonco’s ATO-101™ ([211At] At-anti-CA-IX antibody) targeted alpha therapy candidate in non-muscle invasive bladder cancer (NMIBC).
ATONCO AND MINERVA IMAGING JOIN FORCES IN TARGETING BLADDER CANCER
ATONCO (Saint Herblain, France) and Minerva Imaging (Oelstykke, Denmark), are pleased to announce a close collaboration to combine their strengths to fight bladder cancer.
TARGETED ALPHA THERAPY CANDIDATE : BLADDER CANCER STUDY COMPLETES ENROLMENT
Telix (Melbourne, Australia) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.
IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER
Atonco (Nantes-Saint Herblain, France) and Ionetix (Lansing, MI, USA) have signed a partnership agreement to ensure the manufacturing and GMP supply of the radiopharmaceutical required for the successful completion of Atonco’s clinical studies and commercialization in the United States.
FIRST PATIENT DOSED IN FEASIBILITY STUDY OF TARGETED ALPHATHERAPY FOR BLADDER CANCER
Telix Pharmaceuticals and ATONCO are pleased to announce that the first patient has been treated in the PERTINENCE feasibility study in patients with non-muscle-invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.